Related references
Note: Only part of the references are listed.Lipid Levels and Changes in Body Fat Distribution in Treatment-Naive, HIV-1-Infected Adults Treated With Rilpivirine or Efavirenz for 96 Weeks in the ECHO and THRIVE Trials
Pablo Tebas et al.
CLINICAL INFECTIOUS DISEASES (2014)
Antiretroviral Treatment of Adult HIV Infection 2014 Recommendations of the International Antiviral Society-USA Panel
Huldrych F. Guenthard et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Design and synthesis of a mitochondria-targeting carrier for small molecule drugs
Junyan Han et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2014)
Cytotoxic effect of efavirenz is selective against cancer cells and associated with the cannabinoid system
Markus Hecht et al.
AIDS (2013)
Profile of stress and toxicity gene expression in human hepatic cells treated with Efavirenz
Leysa J. Gomez-Sucerquia et al.
ANTIVIRAL RESEARCH (2012)
Targeting drugs to mitochondria
Anne Heller et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2012)
Visualizing HIV-1 Assembly
Nolwenn Jouvenet et al.
JOURNAL OF MOLECULAR BIOLOGY (2011)
Mitochondrial DNA Depletion and Respiratory Chain Activity in Primary Human Subcutaneous Adipocytes Treated with Nucleoside Analogue Reverse Transcriptase Inhibitors
Metodi V. Stankov et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration
Ganta Vijay Chaitanya et al.
CELL COMMUNICATION AND SIGNALING (2010)
Inhibition of Mitochondrial Function by Efavirenz Increases Lipid Content in Hepatic Cells
Ana Blas-Garcia et al.
HEPATOLOGY (2010)
CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients
Awewura Kwara et al.
AIDS (2009)
CYP2B6 G516T Polymorphism but Not Rifampin Coadministration Influences Steady-State Pharmacokinetics of Efavirenz in Human Immunodeficiency Virus-Infected Patients in South India
Geetha Ramachandran et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
CYP2B6 (c.516G→T) and CYP2A6 (*9B and/or*17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients
Awewura Kwara et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes
Omar Janneh et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
Efavirenz: a decade of clinical experience in the treatment of HIV
Franco Maggiolo
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
The changing shape of mitochondrial apoptosis
Michal Wasilewski et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2009)
Characterization of increased drug metabolism activity in dimethyl sulfoxide (DMSO)-treated Huh7 hepatoma cells
S. Choi et al.
XENOBIOTICA (2009)
Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults
Jean B. Nachega et al.
AIDS (2008)
Clinical impact of patient population differences and genomic variation in efavirenz therapy
Jennifer King et al.
AIDS (2008)
Pharmacogenetics of anti-HIV drugs
A. Telenti et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2008)
Lymphocyte mitochondrial depolarization and apoptosis in HIV-1-infected HAART patients
Leshern Karamchand et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2008)
Intracellular efavirenz levels in peripheral blood mononuclear cells from human immunodeficiency virus-infected individuals
Rie Tanaka et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C
Pablo Barreiro et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
Mitochondrial DNA depletion in HIV-infected patients with chronic hepatitis C and effect of pegylated interferon plus ribavirin therapy
Carmen de Mendoza et al.
AIDS (2007)
Organelle isolation: functional mitochondria from mouse liver, muscle and cultured filroblasts
Christian Frezza et al.
NATURE PROTOCOLS (2007)
Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol
Anna Figueiredo et al.
PLOS PATHOGENS (2006)
Mitochondrial outer membrane permeabilization during apoptosis: the innocent bystander scenario
J. E. Chipuk et al.
CELL DEATH AND DIFFERENTIATION (2006)
Mitochondria: Dynamic organelles in disease, aging, and development
David C. Chan
CELL (2006)
Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals
LM Almond et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Proteomics analysis of human astrocytes expressing the HIV protein Tat
CB Pocernich et al.
MOLECULAR BRAIN RESEARCH (2005)
Mitochondrial toxicity of NRTI antiviral drugs: An integrated cellular perspective
W Lewis et al.
NATURE REVIEWS DRUG DISCOVERY (2003)
Mitochondrial membrane potential regulates matrix configuration and cytochrome c release during apoptosis
E Gottlieb et al.
CELL DEATH AND DIFFERENTIATION (2003)
Regulation of the Apaf-1/Caspase-9 apoptosome by caspase-3 and XIAP
H Zou et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
The mitochondrial membrane potential (Δψm) in apoptosis;: an update
JD Ly et al.
APOPTOSIS (2003)
Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: An update
C Soldani et al.
APOPTOSIS (2002)
Induction of apoptosis by a nonnucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitor
AA Pilon et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
New developments in anti-HIV chemotherapy
E De Clercq
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2002)
Determination of efavirenz, a selective non-nucleoside reverse transcriptase inhibitor, in human plasma using HPLC with post-column photochemical derivatization and fluorescence detection
CZ Matthews et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2002)
Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients
HCF Coté et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Cytochrome c release from mitochondria proceeds by a two-step process
M Ott et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Mitochondria-targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis
O Sordet et al.
BLOOD (2001)
Development and validation of a reverse-phase HPLC method for analysis of efavirenz and its related substances in the drug substance and in a capsule formulation
ER Montgomery et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2001)
Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis
R Detels et al.
AIDS (2001)
Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients
C Marzolini et al.
AIDS (2001)
Adverse effects of antiretroviral therapy
A Carr et al.
LANCET (2000)
Share Paper
